156 related articles for article (PubMed ID: 27956535)
1. NCCN Guidelines Insights: Chronic Myeloid Leukemia, Version 1.2017.
Pallera A; Altman JK; Berman E; Abboud CN; Bhatnagar B; Curtin P; DeAngelo DJ; Gotlib J; Hagelstrom RT; Hobbs G; Jagasia M; Kantarjian HM; Kropf P; Metheny L; Moore JO; Ontiveros E; Purev E; Quiery A; Reddy VV; Rose MG; Shah NP; Smith BD; Snyder DS; Sweet KL; Tibes R; Yang DT; Gregory K; Sundar H; Deininger M; Radich JP
J Natl Compr Canc Netw; 2016 Dec; 14(12):1505-1512. PubMed ID: 27956535
[TBL] [Abstract][Full Text] [Related]
2. Pregnancy in Patients With Chronic Myeloid Leukemia.
Berman E
J Natl Compr Canc Netw; 2018 May; 16(5S):660-662. PubMed ID: 29784750
[TBL] [Abstract][Full Text] [Related]
3. Chronic myelogenous leukemia, version 1.2015.
O'Brien S; Radich JP; Abboud CN; Akhtari M; Altman JK; Berman E; Curtin P; DeAngelo DJ; Deininger M; Devine S; Fathi AT; Gotlib J; Jagasia M; Kropf P; Moore JO; Pallera A; Reddy VV; Shah NP; Smith BD; Snyder DS; Wetzler M; Gregory K; Sundar H
J Natl Compr Canc Netw; 2014 Nov; 12(11):1590-610. PubMed ID: 25361806
[TBL] [Abstract][Full Text] [Related]
4. Management of chronic myelogenous leukemia in pregnancy.
Bhandari A; Rolen K; Shah BK
Anticancer Res; 2015 Jan; 35(1):1-11. PubMed ID: 25550528
[TBL] [Abstract][Full Text] [Related]
5. Chronic myeloid leukemia patients in Tunisia: epidemiology and outcome in the imatinib era (a multicentric experience).
Ben Lakhal R; Ghedira H; Bellaaj H; Ben Youssef Y; Menif S; Manai Z; Bedoui M; Lakhal A; M'Sadek F; Elloumi M; Khélif A; Ben Romdhane N; Laatiri MA; Ben Othmen T; Meddeb B
Ann Hematol; 2018 Apr; 97(4):597-604. PubMed ID: 29305630
[TBL] [Abstract][Full Text] [Related]
6. Managing pregnancy in chronic myeloid leukaemia.
Palani R; Milojkovic D; Apperley JF
Ann Hematol; 2015 Apr; 94 Suppl 2():S167-76. PubMed ID: 25814083
[TBL] [Abstract][Full Text] [Related]
7. Initial treatment for patients with CML.
Goldman JM
Hematology Am Soc Hematol Educ Program; 2009; ():453-60. PubMed ID: 20008231
[TBL] [Abstract][Full Text] [Related]
8. Differentiating factors in treatment-free remission trials: impact of study design on results and clinical applications.
Ritchie EK
Leuk Lymphoma; 2019 May; 60(5):1116-1125. PubMed ID: 30481083
[TBL] [Abstract][Full Text] [Related]
9. Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate.
Brave M; Goodman V; Kaminskas E; Farrell A; Timmer W; Pope S; Harapanhalli R; Saber H; Morse D; Bullock J; Men A; Noory C; Ramchandani R; Kenna L; Booth B; Gobburu J; Jiang X; Sridhara R; Justice R; Pazdur R
Clin Cancer Res; 2008 Jan; 14(2):352-9. PubMed ID: 18223208
[TBL] [Abstract][Full Text] [Related]
10. Pregnancy: part of life in chronic myelogenous leukemia.
Law AD; Dong Hwan Kim D; Lipton JH
Leuk Lymphoma; 2017 Feb; 58(2):280-287. PubMed ID: 27389567
[TBL] [Abstract][Full Text] [Related]
11. Advanced phase chronic myeloid leukaemia (CML) in the tyrosine kinase inhibitor era - a report from the Swedish CML register.
Söderlund S; Dahlén T; Sandin F; Olsson-Strömberg U; Creignou M; Dreimane A; Lübking A; Markevärn B; Själander A; Wadenvik H; Stenke L; Richter J; Höglund M
Eur J Haematol; 2017 Jan; 98(1):57-66. PubMed ID: 27428357
[TBL] [Abstract][Full Text] [Related]
12. Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity.
Schiffer CA; Cortes JE; Hochhaus A; Saglio G; le Coutre P; Porkka K; Mustjoki S; Mohamed H; Shah NP
Cancer; 2016 May; 122(9):1398-407. PubMed ID: 26998677
[TBL] [Abstract][Full Text] [Related]
13. Outcome of 3 pregnancies in a patient with chronic myeloid leukemia who received 3 types of tyrosine kinase inhibitors each in different pregnancy: follow-up of the case with a review of published reports.
Alizadeh H; Jaafar H; Kajtár B
Ann Saudi Med; 2015; 35(6):468-71. PubMed ID: 26657232
[TBL] [Abstract][Full Text] [Related]
14. Dasatinib: from treatment of imatinib-resistant or -intolerant patients with chronic myeloid leukemia to treatment of patients with newly diagnosed chronic phase chronic myeloid leukemia.
Abbott BL
Clin Ther; 2012 Feb; 34(2):272-81. PubMed ID: 22285209
[TBL] [Abstract][Full Text] [Related]
15. Imatinib cessation in children and adolescents with chronic myeloid leukemia in chronic phase.
Millot F; Claviez A; Leverger G; Corbaciglu S; Groll AH; Suttorp M
Pediatr Blood Cancer; 2014 Feb; 61(2):355-7. PubMed ID: 24106110
[TBL] [Abstract][Full Text] [Related]
16. Imatinib Intolerance Is Associated With Blastic Phase Development in Philadelphia Chromosome-Positive Chronic Myeloid Leukemia.
Ángeles-Velázquez JL; Hurtado-Monroy R; Vargas-Viveros P; Carrillo-Muñoz S; Candelaria-Hernández M
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S82-5. PubMed ID: 27521331
[TBL] [Abstract][Full Text] [Related]
17. Current concerns of undertreatment and overtreatment in chronic myeloid leukemia based on European LeukemiaNet 2013 recommendations.
Haznedaroglu IC
Expert Opin Pharmacother; 2013 Oct; 14(15):2005-10. PubMed ID: 23984805
[TBL] [Abstract][Full Text] [Related]
18. NCCN and ELN: What do the guidelines tell us?
Sweet K; Pinilla-Ibarz J
Best Pract Res Clin Haematol; 2016 Sep; 29(3):264-270. PubMed ID: 27839567
[TBL] [Abstract][Full Text] [Related]
19. A prospective analysis of clinical efficacy and safety in chronic myeloid leukemia-chronic phase patients with imatinib resistance or intolerance as evaluated using European LeukemiaNet 2013 criteria.
Murai K; Akagi T; Shimosegawa K; Sugawara T; Ishizawa K; Ito S; Murai K; Motegi M; Yokoyama H; Noji H; Tajima K; Kimura J; Chou T; Ogawa K; Harigae H; Kubo K; Oba K; Sakamoto J; Ishida Y
Eur J Haematol; 2015 Dec; 95(6):558-65. PubMed ID: 25703064
[TBL] [Abstract][Full Text] [Related]
20. Treating the chronic-phase chronic myeloid leukemia patient: which TKI, when to switch and when to stop?
Patel AB; Wilds BW; Deininger MW
Expert Rev Hematol; 2017 Jul; 10(7):659-674. PubMed ID: 28511567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
